ASH22-Program for fremlæggelse af data på Genmabs lægemidler
-
Genmab Announces Multiple Abstracts to be Presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Nov 3, 2022 at 2:01 PM CETMedia Release
Copenhagen, Denmark, November 3, 2022
Nineteen abstracts accepted, including multiple presentations on the safety and efficacy of investigational epcoritamab (DuoBody
-CD3xCD20) in a variety of treatment settings and hematologic malignancies
Four oral presentations highlighting data evaluating epcoritamab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), R/R follicular lymphoma (FL), previously untreated FL, and Richter's syndrome
New data evaluating investigational medicines in Genmab's early portfolio of cancer immunotherapies will also be presented
Genmab to host 2022 R&D Update and ASH Data Review meeting December 12Se hele programmet for Genmab/ASH:
-
Janssen Presents First Data fromMajesTEC-2 Trial of TECVAYLI (teclistamab-cqyv) in Combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
-
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
-
ASH 2022: Talquetamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Re...
Recorded @ ASH 2022 PressBriefing, December 10/ More Info from ASH @ https://oncoletter.ch
-
Monumen-TAL - I dismantle the ASH/ NEJM Talquetamab study ' First of the ASH 2022 video series
-
Talquetamab Generates High Response Rate in Hard-to-Treat Multiple Myeloma .
-
Genmab Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody
-CD3xCD20) in Patients Across a Broad Ran -
Genmab præsenterer lovende data for kræfthåb på konference i USA
-
Genmab har netop præsenteret stærke data på Annual Meeting and Exposition of the American Society of Hematology (ASH). Hør mere i denne video med Helge Larsen.
Disclaimer: Dette er ikke en anbefaling om køb eller salg af aktien. Helge Larsen har aktier i Genmab.
-
Genmab to Hold 2022 R&D Update and ASH Data Review Meeting https://www.proinvestor.com/investornyt
-
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX
(daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...
(www.prnewswire.com)
-
2022 R&D Update and ASH Data Review Dec 12, 2022 at 8:00 PM EST Genmab hosted its 2022 R&D Update and ASH Data Review on Monday, December 12, 2022.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind